GlennDranoffMD

Oncology • Boston, MA

Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Are you Dr. Dranoff?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
44 Binney St
Boston, MA 02115
Phone+1 617-632-5051

Fax+1 617-632-5167

Summary

Dr. Glenn Dranoff, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1991
Massachusetts General HospitalInternship, Internal Medicine, 1985 - 1986
Duke University School of MedicineClass of 1985

Certifications & Licensure

MA State Medical License 1988 - 2025

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2004

Publications & Presentations

PubMed

A phase I trial of vaccination with lethally irradiated lymphoma cells admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells for the treat...
Eric Jacobsen, Ashley Plant, Robert Redd, Philippe Armand, Mikaela McDonough
Leukemia & Lymphoma. 2024-12-01
Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer.
Slavica Dimitrieva, Jon M Harrison, Jonathan Chang, Michelle Piquet, Mari Mino-Kenudson
Cancer Research Communications. 2024-12-01
7 citations
A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction.
Pamela Y Ting, Sneha Borikar, John Ryan Kerrigan, Noel M Thomsen, Eamon Aghania
Science. 2024-07-05

Press Mentions

Atavistik Bio Announces $60 Million Series a Financing to Advance Genetically-Validated Targets in Metabolic Diseases and CancerAugust 24th, 2021
Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand Its PipelineNovember 19th, 2020
Cancer Research Institute Names New Stars of Cancer Immunotherapy ResearchJune 21st, 2019
Join now to see all